Universal Beteiligungs und Servicegesellschaft mbH Cuts Position in Jazz Pharmaceuticals PLC $JAZZ

Universal Beteiligungs und Servicegesellschaft mbH decreased its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 15.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 65,098 shares of the specialty pharmaceutical company’s stock after selling 11,473 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.11% of Jazz Pharmaceuticals worth $8,580,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. LSV Asset Management raised its holdings in shares of Jazz Pharmaceuticals by 3.6% in the 2nd quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company’s stock valued at $271,003,000 after purchasing an additional 87,576 shares in the last quarter. Ameriprise Financial Inc. raised its stake in Jazz Pharmaceuticals by 11.4% in the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after buying an additional 191,637 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Jazz Pharmaceuticals by 3.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,721,294 shares of the specialty pharmaceutical company’s stock worth $182,664,000 after buying an additional 59,252 shares during the last quarter. Vestal Point Capital LP purchased a new stake in Jazz Pharmaceuticals during the 2nd quarter worth about $127,344,000. Finally, Geode Capital Management LLC boosted its position in shares of Jazz Pharmaceuticals by 1.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,171,755 shares of the specialty pharmaceutical company’s stock worth $124,366,000 after acquiring an additional 16,757 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on JAZZ. Robert W. Baird raised their target price on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 18th. Truist Financial increased their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 29th. Bank of America upped their target price on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Finally, Needham & Company LLC increased their target price on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Thirteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $205.67.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $168.71 on Monday. The company’s 50 day simple moving average is $170.14 and its 200-day simple moving average is $142.06. The firm has a market cap of $10.25 billion, a PE ratio of -27.79, a price-to-earnings-growth ratio of 0.92 and a beta of 0.27. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $182.99. The company has a current ratio of 1.65, a quick ratio of 1.44 and a debt-to-equity ratio of 1.09.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 77,500 shares of the firm’s stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $177.81, for a total transaction of $13,780,275.00. Following the transaction, the director directly owned 393,332 shares of the company’s stock, valued at approximately $69,938,362.92. This trade represents a 16.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Patricia Carr sold 5,319 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $182.06, for a total transaction of $968,377.14. Following the completion of the sale, the chief accounting officer directly owned 7,012 shares of the company’s stock, valued at $1,276,604.72. The trade was a 43.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 123,791 shares of company stock worth $21,991,850 in the last three months. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.